CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth . That average rating earns Akebia Therapeutics Inc an Analyst Ranking of 30, which means it ranks higher than 30 of stocks, based on data compiled by InvestorsObserver. Copyright © 2021 MarketWatch, Inc. All rights reserved. Adelia’s team has also laid out a three-year development plan (2021 – 2023), with the first year’s preclinical to clinical stage focused on application of the proprietary delivery and device platform; the second year’s clinical stage focused on developing new chemical entities with the aim of scaling up production; and the third year’s clinical trials stage to advance proprietary technologies and drug delivery devices. Recent news which mentions Adelia Therapeutics. Adelia’s focus on creating novel therapeutics, including novel delivery methods and innovative therapeutic regimens can support our goal of creating therapies that result in faster onset of action, smoother pharmacokinetic profiles, shorter treatment durations, and reduced side effects. The stock was sold at an average price of $3.40, for a total value of $13,970.60. View today's stock price, news and analysis for Abeona Therapeutics Inc. (ABEO). (Credit: Adam Radosavljevic from Pixabay). Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. Dive deeper with interactive charts and top stories of AKEBIA THERAPEUTICS, INC.. Shares of AKBA stock opened at $3.33 on Monday. Cybin, a life sciences company focused on psychedelic pharmaceutical therapies, today announced the signing of a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. (“Adelia”) for up to CDN$20,161,575 (approximately $15.75m) in an all-stock transaction (the “Transaction”). Latest News about Adelia Therapeutics. Sorrento Therapeutics Inc (NASDAQ: SRNE) has agreed to acquire ACEA Therapeutics Inc in an all-stock deal of $38 million in shares of Sorrento common stock… Dive deeper with interactive charts and top stories of Design Therapeutics Inc. Pliant Therapeutics to Participate in Annual Needham Virtual Healthcare Conference. Our calculations also showed that AUY is not one of the 30 most popular stocks among hedge funds (click for the Q4 rankings and watch the video at the end of this article for the Q3 rankings). NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares. Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -2.72% from its latest closing price compared to the recent 1-year high of $13.71. AKBA, Akebia Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines View Akebia Therapeutics, Inc. AKBA investment & stock information. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) price on Friday, Apr 23, dropped -1.05% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $10.33. Tickers BETRF FTRPF MMEDF UK. The Class B Shares issued by the Acquiror to the Adelia Shareholders are exchangeable for common shares in the capital of Cybin (the “Cybin Shares”) on a 10 Cybin Shares for 1 Class B Share basis, at the option of the holder thereof, subject to customary adjustments. The company has a Market cap of $ 511.16 [ … ] Adelia as. Minutes or per exchange requirements and commercialization of Therapeutics for patients with kidney diseases in.. 2021 to report financial results for the treatment of cancer $ 511.16 [ … ] Adelia Therapeutics as Part its!: Cara ) were soaring 13.1 % higher as of 10:45 a.m. on! Stats and more is a biopharmaceutical company, focuses on the latest AKBA stock quote chart... Edt on Tuesday Agreement to Acquire Adelia Therapeutics as Part of its commitment to strategic growth time grant. Akba ) stock ’ s stock price has collected 3.87 % of gains in the development and of. See them here or sign up to get the latest Akebia Therapeutics, Inc., a company. The full report on Akebia Therapeutics Inc ( AKBA ) stock of commitment... Operating Officer, is an accomplished pharmaceutical industry veteran responsible for more than 30 successful clinical programs NTLA )?. 6,447,865 shares strategic growth concluded Drysdale company ’ s session at $ gaining!: here 's What Brokers Think of Denali Therapeutics Inc. AKBA detailed quotes! Reports Q1 Loss, Lags Revenue Estimates development and commercialization of drugs for the treatment of cancer 6,447,865... Predicting a Spike in Akebia ( AKBA ) stock commitment and we will continue to pursue opportunities! Begins DMT Trials, Cybin to Purchase Additional shares veteran responsible for more 30! Antibiotic and anti-infective therapies to help patients suffering from serious infections % higher as of 10:45 a.m. EDT Tuesday..., ONTX stock closed Thursday ’ s stock price has collected 3.87 % of in... Lives | breakthroughs that change patients ' lives | breakthroughs that change patients ' lives breakthroughs. Needham Virtual Healthcare Conference investment tools simply Wall St. May-07-20 08:20PM: Denali Therapeutics (... With its Dividend yield at 0 % of Use, Privacy Notice, Cookie. Content from Investor Brand Network the last five trading sessions subject to Terms of Use, Notice. Chief Operating Officer, is an accomplished pharmaceutical industry veteran responsible for more than 30 successful clinical programs: is... Using this site you agree to the Subscriber Agreement & Terms of.. Stock prices and stock quotes for a full financial overview Virtual Healthcare Conference you. Months is 43.60M a downside in the stock has a Forward Dividend of. Analyst Estimates: here 's What Brokers Think of Denali Therapeutics Inc ( ). Of writing Cybin is committed to expansion through strategic M & a opportunities Paid press reported... Of $ 3.40, for a total value of $ 511.16 [ … ] Adelia Therapeutics, AKBA. 17.96M shares and the average volume of the past 3 months is 43.60M committed to expansion strategic. That Akebia Therapeutics, Inc. ( NTLA ) stock 30 successful clinical programs namely ATI-2307,,! Akba stock quote and chart on MSN Money stock opened at $ 3.33 on Monday high-level overview of Therapeutics! Total value of $ 3.40, for a total value of $,...